TB500 (Thymosin B4 Acetate)
TB500 is a synthetic, acetylated peptide fragment (Ac-LKKTETQ, amino acids 17–23) of Thymosin Beta-4 (Tβ4)—a naturally occurring 43-amino-acid peptide ubiquitous in mammalian tissues. It retains the core actin-binding domain of full-length Tβ4 and is widely studied for potent regenerative, anti-inflammatory, angiogenic, and cytoprotective effects.
| 2mg*10vials | $55 | 10mg*10vials | $150 |
| 5mg*10vials | $85 |
Product Information
Mechanism of Action (Detailed but Concise)
- Actin regulation (core mechanism)TB500 binds to G‑actin to maintain cytoskeletal flexibility, which supports faster migration of fibroblasts, endothelial cells, and stem cells to damaged tissue sites, enabling efficient repair initiation.
- Strong pro‑angiogenic effectIt upregulates VEGF and supports endothelial cell proliferation and tube formation, boosting blood vessel growth to improve oxygen and nutrient supply to injured or poorly vascularized tissues.
- Potent anti‑inflammatory activityTB500 reduces key pro‑inflammatory cytokines including TNF‑α, IL‑1β, and IL‑6, while increasing anti‑inflammatory signals, thereby reducing swelling, pain, and secondary tissue injury.
- Enhanced tissue regenerationIt promotes collagen remodeling, keratinocyte and muscle cell proliferation, and stem cell mobilization, leading to faster healing, better tissue structure, and reduced scar formation.
- Cytoprotective and anti‑apoptotic effectsIt protects cells from oxidative stress and ischemic damage, inhibits excessive cell death, and helps preserve tissue integrity and function during injury and recovery.
Important Warnings & Safety Considerations
Contraindications
- Known hypersensitivity to TB500 or acetate excipients
- Active or recurrent malignant disease (may enhance angiogenesis and cell migration)
- Pregnancy, lactation, and pediatric use (no safety data)
- Proliferative diabetic retinopathy (may promote pathological blood vessel growth)
- Severe bleeding disorders or concurrent anticoagulant therapy
Precautions
- May increase tissue healing rate; monitor acute injuries for over‑proliferation
- Local injection‑site reactions may occur
- Not intended for oral use; no oral bioavailability
- Long‑term safety in humans remains incompletely characterized
Common Adverse Reactions
- Temporary redness, itching, or mild pain at injection site
- Transient fatigue or lethargy
- Mild headache or flushing
- Temporary muscle soreness (rare)
